This year’s most-read articles on CKD highlighted research and insights on drug approvals, guidelines, and value-based care.

Dimerix completes patient enrolment in ACTION3 phase 3 trial of DMX-200 to treat focal segmental glomerulosclerosis: Melbourne, Australia Tuesday, December 16, 2025, 18:00 Hrs [IS ...

Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patientThe ACTION3 Phase 3 trial explores the efficacy and safety ...

ACTION3 is a pivotal multicentre, randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in ...

Kidneys silently filter waste, but signs like bubbly urine, puffy ankles, high blood pressure, and frequent nighttime ...

Clinicians face exciting new options in immunoglobulin A (IgA) nephropathy, with recent accelerated FDA approvals and ...

Sobi® (STO: SOBI) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted ...

The novel drug atacicept was associated with significant reductions in proteinuria vs. placebo with comparable safety and no ...

Among patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis (MPGN), ...

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, ...

At the American Society of Nephrology Kidney Week meeting, interim results from the phase III ORIGIN 3 trial showed that ...